Global IGY Polyclonal Antibodies Market Insights, Research Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 110

Report ID: 5305

Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them.
IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation process of IgY is also different from IgG. These biological features underlie IgY's competitive advantages over IgG. Shown in the four panels are several comparisons between IgY and IgG.
IgY is a hen egg polyclonal antibody. Hen eggs contain more than 450 separate antibodies and when consumed, are not rejected by the human immune system.
North America is the largest consumption place, with a consumption market share nearly 37.5% in 2017; Europe is the second largest consumption place with the consumption market share of 30% in 2017.
The global IGY Polyclonal Antibodies market is valued at 4 million US$ in 2018 and will reach 12 million US$ by the end of 2025, growing at a CAGR of 13.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the IGY Polyclonal Antibodies market based on company, product type, end user and key regions.

This report studies the global market size of IGY Polyclonal Antibodies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of IGY Polyclonal Antibodies in these regions.
This research report categorizes the global IGY Polyclonal Antibodies market by top players/brands, region, type and end user. This report also studies the global IGY Polyclonal Antibodies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Merck
IGY Life Sciences
Abcam
Genway Biotech
Good Biotech
Gallus Immunotech
Creative Diagnostics
Agrisera
Innovagen AB
Capra Science
YO Proteins
GeneTex

Market size by Product
Primary Antibody
Secondary Antibody
Market size by End User
Academic Research
Commercial

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global IGY Polyclonal Antibodies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of IGY Polyclonal Antibodies market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global IGY Polyclonal Antibodies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of IGY Polyclonal Antibodies submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of IGY Polyclonal Antibodies are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of IGY Polyclonal Antibodies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 IGY Polyclonal Antibodies Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global IGY Polyclonal Antibodies Market Size Growth Rate by Product
1.4.2 Primary Antibody
1.4.3 Secondary Antibody
1.5 Market by End User
1.5.1 Global IGY Polyclonal Antibodies Market Size Growth Rate by End User
1.5.2 Academic Research
1.5.3 Commercial
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global IGY Polyclonal Antibodies Market Size
2.1.1 Global IGY Polyclonal Antibodies Revenue 2014-2025
2.1.2 Global IGY Polyclonal Antibodies Sales 2014-2025
2.2 IGY Polyclonal Antibodies Growth Rate by Regions
2.2.1 Global IGY Polyclonal Antibodies Sales by Regions
2.2.2 Global IGY Polyclonal Antibodies Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 IGY Polyclonal Antibodies Sales by Manufacturers
3.1.1 IGY Polyclonal Antibodies Sales by Manufacturers
3.1.2 IGY Polyclonal Antibodies Sales Market Share by Manufacturers
3.1.3 Global IGY Polyclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.2 IGY Polyclonal Antibodies Revenue by Manufacturers
3.2.1 IGY Polyclonal Antibodies Revenue by Manufacturers (2014-2019)
3.2.2 IGY Polyclonal Antibodies Revenue Share by Manufacturers (2014-2019)
3.3 IGY Polyclonal Antibodies Price by Manufacturers
3.4 IGY Polyclonal Antibodies Manufacturing Base Distribution, Product Types
3.4.1 IGY Polyclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers IGY Polyclonal Antibodies Product Type
3.4.3 Date of International Manufacturers Enter into IGY Polyclonal Antibodies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global IGY Polyclonal Antibodies Sales by Product
4.2 Global IGY Polyclonal Antibodies Revenue by Product
4.3 IGY Polyclonal Antibodies Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global IGY Polyclonal Antibodies Breakdown Data by End User

6 North America
6.1 North America IGY Polyclonal Antibodies by Countries
6.1.1 North America IGY Polyclonal Antibodies Sales by Countries
6.1.2 North America IGY Polyclonal Antibodies Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America IGY Polyclonal Antibodies by Product
6.3 North America IGY Polyclonal Antibodies by End User

7 Europe
7.1 Europe IGY Polyclonal Antibodies by Countries
7.1.1 Europe IGY Polyclonal Antibodies Sales by Countries
7.1.2 Europe IGY Polyclonal Antibodies Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe IGY Polyclonal Antibodies by Product
7.3 Europe IGY Polyclonal Antibodies by End User

8 Asia Pacific
8.1 Asia Pacific IGY Polyclonal Antibodies by Countries
8.1.1 Asia Pacific IGY Polyclonal Antibodies Sales by Countries
8.1.2 Asia Pacific IGY Polyclonal Antibodies Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific IGY Polyclonal Antibodies by Product
8.3 Asia Pacific IGY Polyclonal Antibodies by End User

9 Central & South America
9.1 Central & South America IGY Polyclonal Antibodies by Countries
9.1.1 Central & South America IGY Polyclonal Antibodies Sales by Countries
9.1.2 Central & South America IGY Polyclonal Antibodies Revenue by Countries
9.1.3 Brazil
9.2 Central & South America IGY Polyclonal Antibodies by Product
9.3 Central & South America IGY Polyclonal Antibodies by End User

10 Middle East and Africa
10.1 Middle East and Africa IGY Polyclonal Antibodies by Countries
10.1.1 Middle East and Africa IGY Polyclonal Antibodies Sales by Countries
10.1.2 Middle East and Africa IGY Polyclonal Antibodies Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa IGY Polyclonal Antibodies by Product
10.3 Middle East and Africa IGY Polyclonal Antibodies by End User

11 Company Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Company Business Overview
11.1.3 Merck IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Merck IGY Polyclonal Antibodies Products Offered
11.1.5 Merck Recent Development
11.2 IGY Life Sciences
11.2.1 IGY Life Sciences Company Details
11.2.2 Company Business Overview
11.2.3 IGY Life Sciences IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.2.4 IGY Life Sciences IGY Polyclonal Antibodies Products Offered
11.2.5 IGY Life Sciences Recent Development
11.3 Abcam
11.3.1 Abcam Company Details
11.3.2 Company Business Overview
11.3.3 Abcam IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Abcam IGY Polyclonal Antibodies Products Offered
11.3.5 Abcam Recent Development
11.4 Genway Biotech
11.4.1 Genway Biotech Company Details
11.4.2 Company Business Overview
11.4.3 Genway Biotech IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Genway Biotech IGY Polyclonal Antibodies Products Offered
11.4.5 Genway Biotech Recent Development
11.5 Good Biotech
11.5.1 Good Biotech Company Details
11.5.2 Company Business Overview
11.5.3 Good Biotech IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Good Biotech IGY Polyclonal Antibodies Products Offered
11.5.5 Good Biotech Recent Development
11.6 Gallus Immunotech
11.6.1 Gallus Immunotech Company Details
11.6.2 Company Business Overview
11.6.3 Gallus Immunotech IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Gallus Immunotech IGY Polyclonal Antibodies Products Offered
11.6.5 Gallus Immunotech Recent Development
11.7 Creative Diagnostics
11.7.1 Creative Diagnostics Company Details
11.7.2 Company Business Overview
11.7.3 Creative Diagnostics IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Creative Diagnostics IGY Polyclonal Antibodies Products Offered
11.7.5 Creative Diagnostics Recent Development
11.8 Agrisera
11.8.1 Agrisera Company Details
11.8.2 Company Business Overview
11.8.3 Agrisera IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Agrisera IGY Polyclonal Antibodies Products Offered
11.8.5 Agrisera Recent Development
11.9 Innovagen AB
11.9.1 Innovagen AB Company Details
11.9.2 Company Business Overview
11.9.3 Innovagen AB IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Innovagen AB IGY Polyclonal Antibodies Products Offered
11.9.5 Innovagen AB Recent Development
11.10 Capra Science
11.10.1 Capra Science Company Details
11.10.2 Company Business Overview
11.10.3 Capra Science IGY Polyclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Capra Science IGY Polyclonal Antibodies Products Offered
11.10.5 Capra Science Recent Development
11.11 YO Proteins
11.12 GeneTex

12 Future Forecast
12.1 IGY Polyclonal Antibodies Market Forecast by Regions
12.1.1 Global IGY Polyclonal Antibodies Sales Forecast by Regions 2019-2025
12.1.2 Global IGY Polyclonal Antibodies Revenue Forecast by Regions 2019-2025
12.2 IGY Polyclonal Antibodies Market Forecast by Product
12.2.1 Global IGY Polyclonal Antibodies Sales Forecast by Product 2019-2025
12.2.2 Global IGY Polyclonal Antibodies Revenue Forecast by Product 2019-2025
12.3 IGY Polyclonal Antibodies Market Forecast by End User
12.4 North America IGY Polyclonal Antibodies Forecast
12.5 Europe IGY Polyclonal Antibodies Forecast
12.6 Asia Pacific IGY Polyclonal Antibodies Forecast
12.7 Central & South America IGY Polyclonal Antibodies Forecast
12.8 Middle East and Africa IGY Polyclonal Antibodies Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 IGY Polyclonal Antibodies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer